Recce Pharmaceuticals Ltd. · ASX:RCE
Recce Pharmaceuticals — Q4 FY26 Earnings Presentation
17 slides from Recce Pharmaceuticals's earnings presentation, Jul 21, 2026
Slide 1: Q4 FY26 Investor Presentation
For personal use only Q4 FY26 Investor Presentation ASX:RCE | FSE:R9Q July 2026 0
Slide 2: Disclaimer
Disclaimer For personal use only DISCLAIMER FUTURE MATTERS This presentation has been prepared by Recce Pharmaceuticals Ltd (the “Company”). It does This presentation contains reference to certain intentions, expectations, future plans, strategy and prospects of not purport to contain all the inform
Slide 3: Company Overview
For personal use only Overview Company
Slide 4: Recce Pharmaceuticals – Company Overview
Recce Pharmaceuticals – Company Overview Recce Pharmaceuticals is a leading, Australian anti-infective company approaching near term commercialisation milestones For personal use only Products address the global healthcare crisis of antibiotic resistance: working faster than traditional antibiotics
Slide 5: Large Addressable Market
Large Addressable Market The global diabetic foot infection (DFI) market represents a substantial burden on global healthcare systems For personal use only US$5.8B Est. global DFI INDONESIA MENA GLOBAL treatment market1 >20 million >84 million >589 million adults in Indonesia with adults in MENA reg
Slide 6: Key highlights for the quarter ended June 2026
Key highlights for the quarter ended 30 June 2026 A transformational quarter delivering regulatory, clinical and commercial milestones that further de-risk Recce's global development strategy For personal use only Clinical Update Regulatory Progress Commercialisation Global Expansion Indonesian BPOM
Slide 7: Registrational Phase Clinical Trial - Australia
Registrational Phase 3 Clinical Trial - Australia Randomised, Active Comparator Study of R327 Topical Gel for the Treatment of Diabetic Foot Infections For personal use only Timeline 2026 2027 2028 R327 Topical Phase 3 R327G Additional Registrational Clinical Trials and Interim Registered in DFI Dat
Slide 8: Routine Regulatory Inspection of Indonesian Sites
Routine Regulatory Inspection of Indonesian Sites For personal use only • Comprehensive regulatory inspection successfully completed for Phase 3 clinical trial site for the treatment of DFIs – Inspection formed part of BPOM’s standard regulatory oversight of clinical studies and included a comprehen
Slide 9: Program Pipeline driven by 1st approval in Diabetic Foot Infections
Program Pipeline* driven by 1st approval in Diabetic Foot Infections 2026 2027 2028 2029 2030 For personal use only Phase 3 Interim Data Readout - 155 patients R327 Topical Positive Indonesian Phase 3 Clinical Trial data readouts, Diabetic Foot Ulcer Infection GEL together with subsequent regulatory
Slide 10: Recce Global Growth Strategy
Recce Global Growth Strategy Indonesian regulatory approval serves as a foundation for a cascading global approval strategy across multiple regions For personal use only Expansion into Expansion across Expansion to Global Approvals ASEAN & MENA Australia/NZ USA/DoD Gel IV Aerosol New Products and DF
Slide 11: Middle Eastern Pharmaceutical Company Term Sheet
Middle Eastern Pharmaceutical Company Term Sheet Recce has signed a non-binding term sheet with a leading Middle Eastern Pharmaceutical Company for a 10-year exclusive For personal use only multi-country licensing agreement for the licensing of R327G through the MENA region Term Sheet Highlights • T
Slide 12: Intellectual Property & Manufacturing
For personal use only Intellectual Property & Manufacturing 11
Slide 13: Robust Worldwide Intellectual Property Portfolio
Robust Worldwide Intellectual Property Portfolio Recce’s patent portfolio contains over 40 patents and patent applications in the world’s major markets. For personal use only Patent Patent Patent Patent Filed Expiry Expiry Expiry Expiry Family 1 Family 2 Family 3 Family 4 Australia ✓ 2028 ✓ 2037 ✓ 2
Slide 14: Share Purchase Plan Now Open and Use of Funds
Share Purchase Plan Now Open and Use of Funds For personal use only Use of Funds and Available Liquidity Event Date Funds raised under the Placement and SPP will be used for the following SPP Record Date 7:00pm (AEST), Thursday, 25 June 2026 activities: SPP Offer Booklet made available to eligible •
Slide 15: Company Financials
Company Financials Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of novel synthetic anti-infectives For personal use only Capital Structure – July 2026 RCE Share Price and Volume Chart – 12 Months (price shown in AUD) 1,600,000 $0.80 ASX & FSE Code RCE, R9Q 1,400,000
Slide 16: Summary
Summary Recce is approaching a number of near term significant value creating opportunities with commercialisation For personal use only Novel, Synthetic, Broad-Spectrum, Approaching pivotal clinical and Upon completion of Phase 3 Rapid-Acting, Anti-Infectives: commercial inflection point with regis
Slide 17: Thank you
For personal use only Thank you recce.com.au
Recce Pharmaceuticals — Q4 FY26 Earnings Presentation on 6ix